GMAB is expected to report earnings to rise+24% to 17 cents per share on May 02

A.I.dvisor
at Tickeron.com
05/01/24
Loading...
GMAB - Genmab A/S ADS
Genmab A/S ADS Earnings Graph
Q1'24
Est.
$0.17
Q4'23
Missed
by $0.17
Q3'23
Est.
$0.47
Q2'23
Beat
by $0.02
Q1'23
Missed
by $0.04
The last earnings report on December 31 showed earnings per share of 14 cents, missing the estimate of 31 cents. P/B Ratio (3.945) is normal, around the industry mean (10.139). P/E Ratio (29.210) is within average values for comparable stocks, (115.202). Projected Growth (PEG Ratio) (1.197) is also within normal values, averaging (1.468). GMAB has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.015). P/S Ratio (7.716) is also within normal values, averaging (226.762). With 933.13K shares outstanding, the current market capitalization sits at 18.28B.
View a ticker or compare two or three
GMABDaily Signal changed days agoGain/Loss if shorted
 
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

an international biotechnology company, which develops human antibody therapeutics for the treatment of cancer and other diseases.

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
Carl Jacobsens Vej 30
Phone
+45 70202728
Employees
2204
Web
https://www.genmab.com